The first rAAV2‐AADC gene therapy study for AADC deficiency was a compassionate use trial in 2012 that has progressed to three further phase I/II clinical trials reporting long‐term efficacy in 2022 (Table 2).41, 42, 43, 44. Here, DDC is linked to aromatic L-amino acid decarboxylase deficiency.